All In Biotech

Drug Trial Radar · NCT07205601

Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's Disease

Phase 2a Assessment of Safety, Tolerability, and Efficacy of Repeated Dosing of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild to Moderate Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

115

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Feb 2029

Study completion Feb 2030

Sponsor

Lead sponsor
Regeneration Biomedical, Inc.Industry
Sponsor type
Industry
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 2 clinical trial is to learn if repeated dosing of RB-ADSC (an investigational autologous cell product obtained from participant's own adipose tissue) enhances the positive preliminary results seen in Phase 1 for the of treatment for mild to moderate Alzheimer's Disease in adults. The clinical trial will also continue to evaluate the safety of repeated dosing of RB-ADSC. This study will primarily evaluate the effects of repeated dosing of RB-ADSC on cognitive performance compared to placebo control. Participants will receive RB-ADSC every 2 months for a total of 6 doses. Participants randomized into the placebo control group will have the option to cross over to receive treatment after completion of the primary phase of the study.

Conditions

  • Alzheimer Disease

Interventions

  • RB-ADSCBiological

    RB-ADSC is an investigational an ex-vivo expanded autologous adipose-derived stem cell product

  • PlaceboOther

    0.9% NaCl USP

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Composite ScoreTime frame: Baseline, Month 6 and Month 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.